Arkolith/Insider Trading/TRDA/Form 4

Wentworth Kory James

Chief Financial OfficerEntrada Therapeutics, Inc. (TRDA) · full profile →Form 4 · filed Dec 3, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$120K
Net Open-Market Flow
-$120K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 2, 2024Option exercise(M)5K$2.10$11K79K
Dec 2, 2024Sell(S)5K$20.00$100K74K
Nov 29, 2024Sell(S)1K$19.97$20K74K
Nov 29, 2024Option exercise(M)1K$2.10$2K75K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 2, 2024Option exercise(M)5K—$031K
Nov 29, 2024Option exercise(M)1K—$036K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001689375-24-000068) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML